John S Munger

Title: John S. Munger: Innovator in Genetic Screening

Introduction

John S. Munger is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of genetic screening, particularly in the study of bioactive peptides. His innovative approach has led to advancements in understanding the mechanisms of latent TGF-β activation.

Latest Patents

Munger holds a patent for a method titled "Genetic screen for bioactive peptides." This patent describes a sophisticated technique for screening proteins involved in the extracellular regulation of latent TGF-β activation. The method involves transducing a cell line with a retroviral cDNA library to create a reporter cell line that produces green fluorescent protein (GFP) in response to TGF-β signaling. Individual clones created by the reporter cell line are grown and co-cultured with a second TGF-β reporter cell line that produces luciferase in response to TGF-β. The luciferase production identifies positive clones, allowing for the identification of mechanisms of latent TGF-β activation employed by these clones.

Career Highlights

John S. Munger is affiliated with New York University, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but has also paved the way for future innovations in genetic screening and therapeutic applications.

Collaborations

Munger has collaborated with notable colleagues, including Daniel B. Rifkin and Justin P. Annes. These collaborations have further enriched his research and expanded the impact of his work in the field.

Conclusion

John S. Munger is a distinguished inventor whose work in genetic screening has significant implications for understanding biological processes. His innovative methods and collaborations continue to influence the scientific landscape.